AstraZeneca's breast cancer drug fails late-stage trial

AZN•2026-09-11

Late-stage breast cancer trial misses primary goal

Sept. 11 (Reuters) - AstraZeneca said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial.

AstraZeneca's breast cancer drug fails late-stage trial

Late-stage breast cancer trial misses primary goal

Related News

P3 Health Partners agrees to sell up to $70 million of preferred stock units with warrants in private placement

Corning enters equity distribution deal with Goldman Sachs for up to $2 billion ATM offering

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Global Self Storage CEO Mark Winmill buys USD 20,618 in common shares

TD appoints Renu Gupta chief strategy and commercial officer